(R,S)-zileuton

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: (R,S)-zileuton
• 英文别名: N-hydroxy-N-(1-benzo[b]thien-2-ylethyl) acetamide；N-(1-Benzo[b]thiophen-2-yl-ethyl)-N-hydroxy-acetamide；N-[1-(1-benzothiophen-2-yl)ethyl]-N-hydroxyacetamide
• 化学式: C₁₂H₁₃NO₂S
• 分子量: 235.307
• InChiKey: QHXPDZPAJHZYNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-acetoxy-N-(1-benzo[b]thien-2-ylethyl) acetamide 、 氢氧化锂 生成 (R,S)-zileuton
  参考文献：
  名称：

  SUMMERS, JAMES B. (JR);GUNN, BRUCE P.;BROOKS, DEE W.

  摘要：

  DOI：

文献信息

• Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
  申请人：Robinson B. Cynthia

  公开号：US20050090455A1

  公开（公告）日：2005-04-28

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a lipoxygenase inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

  一种药物或兽药组合物，包括从去氢表雄酮和/或去氢表雄酮硫酸盐中选择的第一活性成分，以及包括一种脂氧合酶抑制剂的第二活性成分，用于治疗哮喘、慢性阻塞性肺病或其他呼吸系统疾病。该组合物以各种配方形式提供，并以套装形式提供。该专利的产品用于预防和治疗哮喘、慢性阻塞性肺病或其他呼吸系统疾病。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET D'UNE INFLAMMATION
  申请人：KANDULA MAHESH

  公开号：WO2014115098A1

  公开（公告）日：2014-07-31

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological diseases and inflammation, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, neurological diseases and inflammation, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, asthma, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.

  该发明涉及具有化学式I或其药用可接受的盐的化合物，以及其多型、溶剂合物、对映体、立体异构体和水合物。包括化学式I化合物的有效量的药物组合物；以及用于治疗或预防神经系统疾病和炎症、神经系统疾病、过敏、呼吸系统疾病或炎症性疾病的方法，可以制备用于口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射的药物组合物。这些组合物可以用于治疗肌肉障碍、神经系统疾病和炎症、痉挛、神经病性疼痛、纤维肌痛、帕金森病、过敏、哮喘、慢性阻塞性肺病、过敏性鼻炎、头痛、慢性疼痛、亚慢性疼痛和局部疼痛或其相关并发症的治疗。
• COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN
  申请人：Kipp E. James

  公开号：US20070111965A1

  公开（公告）日：2007-05-17

  The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.

  本发明涉及含脂氧化酶抑制剂和环糊精的包含物复合物的配方，具有治疗有效浓度的脂氧化酶抑制剂，制备方法以及使用它们治疗疾病状态的方法。形成环糊精复合物可以增强脂氧化酶抑制剂的水溶性，从而允许在溶液中获得更高浓度的脂氧化酶。脂氧化酶抑制剂-环糊精复合物的水溶性配方适用于静脉或口服给药，用于治疗和/或预防炎症性疾病状态。水溶性配方可以冻干以延长储存稳定性，帮助口服给药和/或提供方便和经济的包装。
• [EN] IMPROVED PROCESS FOR THE PREPARATION OF (±)-1-(1-BENZO[B]THIEN-2-YLETHYL)-1-HYDROXYUREA<br/>[FR] PROCÉDÉ AMÉLIORÉ DESTINÉ À LA PRÉPARATION DE (±)-1-(1-BENZO[B]THIÈN-2-YLÉTHYL)-1-HYDROXYURÉE
  申请人：MSN LAB LTD

  公开号：WO2011036680A2

  公开（公告）日：2011-03-31

  An improved process for the preparation of (±)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea compound of formula (I).

  一种改进的制备(±)-1-(1-苯并[b]噻吩-2-基乙基)-1-羟基脲化合物(I)的过程。
• Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting
  申请人：Abbott Laboratories

  公开号：US04873259A1

  公开（公告）日：1989-10-10

  Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl; wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl; A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 1-5; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl, (23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl; Z is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.

  该公式的化合物：##STR1##其中R.sub.1是（1）氢，（2）C.sub.1到C.sub.4烷基，（3）C.sub.2到C.sub.4烯基或（4）NR.sub.2R.sub.3，其中R.sub.2和R.sub.3分别选择自（1）氢，（2）C.sub.1到C.sub.4烷基和（3）羟基，但R.sub.2和R.sub.3不能同时为羟基；其中X是氧，硫，SO.sub.2或NR.sub.4，其中R.sub.4是（1）氢，（2）C.sub.1到C.sub.6烷基，（3）C.sub.1到C.sub.6烷酰基，（4）芳酰基或（5）烷基磺酰基；A选择自C.sub.1到C.sub.6烷基和C.sub.2到C.sub.6烯基；n为1-5；Y每次独立选择自（1）氢，（2）卤素，（3）羟基，（4）氰基，（5）卤代烷基，（6）C.sub.1到C.sub.12烷基，（7）C.sub.2到C.sub.12烯基，（8）C.sub.1到C.sub.12烷氧基，（9）C.sub.3到C.sub.8环烷基，（10）C.sub.1-C.sub.8硫代烷基，（11）芳基，（12）芳氧基，（13）芳酰基，（14）C.sub.1到C.sub.12芳基烷基，（15）C.sub.2到C.sub.12芳基烯基，（16）C.sub.1到C.sub.12芳基烷氧基，（17）C.sub.1到C.sub.12芳基硫代烷氧基，以及取代衍生物的（18）芳基，（19）芳氧基，（20）芳酰基，（21）C.sub.1到C.sub.12芳基烷基，（22）C.sub.2到C.sub.12芳基烯基，（23）C.sub.1到C.sub.12芳基烷氧基或（24）C.sub.1到C.sub.12芳基硫代烷氧基，其中取代基选择自卤素，硝基，氰基，C.sub.1到C.sub.12烷基，烷氧基和卤代烷基；Z是氧或硫；M是氢，药学上可接受的阳离子，芳酰基或C.sub.1到C.sub.12烷酰基，是5-和/或12-脂氧合酶酶的有效抑制剂。还公开了抑制脂氧合酶活性的脂氧合酶抑制剂组合物和方法。